scholarly journals Highly luminescent dual mode rare-earth nanorod assisted multi-stage excitable security ink for anti-counterfeiting applications

2014 ◽  
Vol 2 (48) ◽  
pp. 10468-10475 ◽  
Author(s):  
Pawan Kumar ◽  
Jaya Dwivedi ◽  
Bipin Kumar Gupta
Keyword(s):  
Rare Earth ◽  
Dual Mode ◽  
Multi Stage ◽  
New Strategy

Demonstration of new strategy for designing multi-stage excitable highly-luminescent Y2O3:Yb3+/Er3+ nanorod assisted security ink for protection against counterfeiting.

scholarly journals Self-assembly induced luminescence of Eu3+-complexes and application in bioimaging

2021 ◽  
Author(s):  
Ping-Ru Su ◽  
Tao Wang ◽  
Pan-Pan Zhou ◽  
Xiao-Xi Yang ◽  
Xiao-Xia Feng ◽  
...  
Keyword(s):  
Aqueous Solution ◽  
Rare Earth ◽  
Luminescence Intensity ◽  
Self Assembly ◽  
Room Temperature ◽  
Molecular Motion ◽  
Proof Of Concept ◽  
Room Temperature Phosphorescence ◽  
New Strategy ◽  
Size Controlled

Abstract Design and engineering of highly efficient emitting materials with assembly-induced luminescence, such as room temperature phosphorescence (RTP) and aggregation-induced emission (AIE), have stimulated extensive efforts. Here, we propose a new strategy to obtain size-controlled Eu3+-complex nanoparticles (Eu-NPs) with self-assembly induced luminescence (SAIL) characteristics without encapsulation or hybridization. Compared with previous RTP or AIE materials, the SAIL phenomena of increased luminescence intensity and lifetime in aqueous solution for the proposed Eu-NPs are due to the combined effect of self-assembly in confining the molecular motion and shielding the water quenching. As a proof of concept, we also show that this system can be further applied in bioimaging, temperature measurement and HClO sensing. The SAIL activity of the rare-earth (RE) system proposed here offers a further step forward on the roadmap for the development of RE light conversion systems and their integration in bioimaging and therapy applications.

Separation of samarium from medium rare earth mixture using multi-stage counter-current extraction

2020 ◽  
pp. 1-11 ◽  
Author(s):  
Nurul Ain Ismail ◽  
Mohd Aizudin Abd Aziz ◽  
Anwaruddin Hisyam ◽  
Mohammad Alwi Abidin
Keyword(s):  
Rare Earth ◽  
Multi Stage ◽  
Counter Current

Dual mode emission of core–shell rare earth nanoparticles for fluorescence encoding

2015 ◽  
Vol 3 (24) ◽  
pp. 6314-6321 ◽  
Author(s):  
Huan Chen ◽  
Yanbo Lang ◽  
Yongling Zhang ◽  
Dan Zhao ◽  
Guanshi Qin ◽  
...  
Keyword(s):  
Rare Earth ◽  
Water Soluble ◽  
Core Shell ◽  
Dual Mode ◽  
Rare Earth Nanoparticles

We have synthesized water soluble dual mode emission (upconversion and downconversion) core–shell rare earth nanoprobes (∼30 nm) for fluorescence encoding.

Dual-Mode Luminescent Nanopaper Based on Ultrathin g–C3N4 Nanosheets Grafted with Rare-Earth Upconversion Nanoparticles

2016 ◽  
Vol 8 (33) ◽  
pp. 21555-21562 ◽  
Author(s):  
Yafei Zhao ◽  
Ruoyan Wei ◽  
Xin Feng ◽  
Lining Sun ◽  
Panpan Liu ◽  
...  
Keyword(s):  
Rare Earth ◽  
Upconversion Nanoparticles ◽  
Dual Mode

Waste heat driven dual-mode, multi-stage, multi-bed regenerative adsorption system

2003 ◽  
Vol 26 (7) ◽  
pp. 749-757 ◽  
Author(s):  
B.B. Saha ◽  
S. Koyama ◽  
T. Kashiwagi ◽  
A. Akisawa ◽  
K.C. Ng ◽  
...  
Keyword(s):  
Waste Heat ◽  
Adsorption System ◽  
Dual Mode ◽  
Multi Stage

FOCUS4: A prospective molecularly stratified, adaptive multicenter program of randomized controlled trials for patients with colorectal cancer (CRC).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. TPS3645-TPS3645
Author(s):  
Kai-Keen Shiu ◽  
Tim Maughan ◽  
Richard H. Wilson ◽  
Richard A. Adams ◽  
Cheryl Pugh ◽  
...  
Keyword(s):  
Randomised Trial ◽  
Gene Mutations ◽  
Progression Free Survival ◽  
Predictive Biomarker ◽  
Double Blind ◽  
Interim Analyses ◽  
Pten Loss ◽  
Molecular Stratification ◽  
Multi Stage ◽  
New Strategy

TPS3645 Background: Targeted therapies based on somatic gene mutations or activated pathways have inhibited progression of some cancers. However, although various targets are identifiable in CRC, KRAS mutation is currently the only validated predictive biomarker for selection of a targeted therapy. FOCUS4 is a rolling phase II-III trial for testing in a staged way both the utility of molecular stratification and the efficacy of novel agents in subpopulations of mCRC patients. It is also a trial of a new strategy for testing stratified approaches to therapy in any biologically complex tumour type using a Multi-Arm, Multi-Stage design. Methods: The study population consists of subjects with newly diagnosed inoperable mCRC. Subjects receive first-line chemotherapy for 16 weeks. During this time the tumour is tested for BRAF/PIK3CA/KRAS/NRAS mutations and PTEN loss. Subjects with responding or stable disease on CT, who would normally be candidates for a treatment break, are then randomised to four coherent biomarker-based subgroups: FOCUS4-A: BRAF mutant, FOCUS4-B: PIK3CA mutant or complete loss of PTEN on IHC, FOCUS4-C: KRAS or NRAS mutant, FOCUS4-D: All wild type (no mutations of BRAF, PIK3CA, KRAS or NRAS). For each subgroup, a relevant novel agent or combination is to be tested in an adaptive double-blind placebo controlled randomised trial design with multiple interim analyses for early termination if there is no strong evidence of worthwhile activity. There will also be a 5thsubgroup FOCUS4-N testing maintenance capecitabine for unclassifiable tumours or for patients whose marker defined cohort is temporarily suspended. The primary endpoint is progression free survival. Promising results in any biomarker defined cohort will then be tested for response in cohorts without the biomarker. Within the overall trial, biomarker developments can be accommodated with changes in the distribution of the cohorts or testing of new targeted agents. Enrolment will commence in May 2013. Upto 3400 patients will be registered over a 4-5 year period depending on which cohorts pass their staged interim analyses and proceed to later stages, including an overall survival endpoint. Clinical trial information: 2012-005111-12.

Dual-mode hydrodynamic railing and arraying of microparticles for multi-stage signal detection in continuous flow biochemical microprocessors

Lab on a Chip ◽  
2014 ◽  
Vol 14 (8) ◽  
pp. 1405-1409 ◽  
Author(s):  
Ryan D. Sochol ◽  
Daniel Corbett ◽  
Sarah Hesse ◽  
William E. R. Krieger ◽  
Ki Tae Wolf ◽  
...  
Keyword(s):  
Signal Detection ◽  
Continuous Flow ◽  
Dual Mode ◽  
Mixing Processes ◽  
Reaction Stage ◽  
Multi Stage

We present a continuous flow microfluidic “rail-trap-and-rail” reactor for passively: (i) executing multi-stage particulate-based mixing processes, and (ii) arraying select particles at each reaction stage.

Sign in / Sign up

Export Citation Format

Share Document